Treatment for Hepatitis B
For chronic hepatitis B, first-line treatment consists of long-term oral nucleos(t)ide analogues with high barrier to resistance—specifically entecavir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF)—while acute hepatitis B typically requires only supportive care unless severe hepatitis or acute liver failure develops. 1, 2, 3
Acute Hepatitis B
Antiviral therapy is generally NOT recommended for uncomplicated acute hepatitis B, as more than 95% of adults spontaneously clear the infection within 4-8 months 4, 5. Early antiviral treatment may actually interfere with protective immune responses and suppress neutralizing antibody production.
Treatment IS indicated only when:
- Persistent severe hepatitis develops
- Acute liver failure occurs
- Signs of hepatic decompensation appear
In these severe cases, oral antiviral therapy (lamivudine or other nucleos(t)ide analogues) should be initiated promptly to prevent progression to liver failure and potential need for transplantation 4.
Chronic Hepatitis B
First-Line Treatment Options
The most recent EASL 2025 and AASLD/ISDA 2026 guidelines establish three preferred nucleos(t)ide analogues as first-line therapy 2, 3:
- Entecavir (0.5-1 mg daily)
- Tenofovir disoproxil fumarate (TDF) (300 mg daily)
- Tenofovir alafenamide (TAF) (25 mg daily)
These agents provide:
- High efficacy (>85-90% virological response after 5 years)
- High barrier to resistance
- Excellent safety profiles
- Convenient once-daily oral administration
- Broad applicability including decompensated cirrhosis
Selecting Among First-Line Agents
Choose based on these specific factors 3:
- Avoid TDF if: Renal disease, bone disease, or declining renal function present
- Avoid ETV if: Pregnancy, prior lamivudine exposure, or HIV coinfection (unless HIV RNA suppressed on antiretroviral therapy)
- Avoid TAF if: Creatinine clearance <15 mL/min and not yet on dialysis
- Adjust doses for: Renal dysfunction or dialysis (ETV and TDF require adjustment; consider switching from TDF if renal function declining)
Treatment Indications
- HBV DNA ≥2,000 IU/mL AND ALT ≥2x upper limit of normal (ULN)
- Any cirrhosis with detectable HBV DNA (regardless of ALT or HBV DNA level)
- Moderate-to-severe histological lesions on biopsy
- Pregnant women with high viremia (HBV DNA >200,000 IU/mL) to prevent mother-to-child transmission
- Patients requiring immunosuppression or chemotherapy (prophylactic treatment)
Additional considerations for treatment:
- HBeAg-positive patients: Delay treatment 3-6 months if compensated disease to assess for spontaneous HBeAg seroconversion 6
- Age >30-40 years with HBeAg-negative infection and evidence of active disease 7, 2
- Healthcare workers requiring HBV DNA <2,000 IU/mL (or <200 IU/mL for exposure-prone procedures) 2
Pegylated Interferon-Alpha Alternative
Pegylated interferon-alpha can be considered as an alternative in mild-to-moderate chronic hepatitis B without cirrhosis 1, 2.
Advantages:
- Finite treatment duration (48-52 weeks)
- Higher rates of HBsAg loss compared to nucleos(t)ide analogues
- No resistance development
Contraindications:
- Decompensated cirrhosis (risk of hepatic decompensation from IFN-related flares) 6
- Compensated cirrhosis (nucleos(t)ide analogues preferred)
- Autoimmune disease
- Uncontrolled psychiatric illness
- Pregnancy
Treatment Duration
Nucleos(t)ide analogue therapy is typically indefinite for most patients 1, 2:
- HBeAg-positive: Minimum 1 year; continue 3-6 months after confirmed HBeAg seroconversion (on two occasions ≥2 months apart), though many require indefinite treatment 6
- HBeAg-negative: Indefinite treatment in most cases 6
- Cirrhosis: Indefinite treatment mandatory 6, 3
Optimal endpoint: HBsAg loss (functional cure), though this occurs in only 3-5% of patients after 10 years of nucleos(t)ide analogue therapy 7, 8
Monitoring During Treatment
Measure HBV DNA every 3-6 months to assess virological response 4:
- Complete virological response at week 24: Continue treatment until endpoint achieved
- Partial virological response at week 24:
- If on low-barrier drug (lamivudine, telbivudine, adefovir): Switch to high-barrier drug (entecavir, TDF, or TAF)
- If on high-barrier drug: Continue with regular monitoring for viral breakthrough
- Viral breakthrough: Implement rescue therapy based on genotypic resistance testing 4
Special Populations
Decompensated cirrhosis:
- Nucleos(t)ide analogues are treatment of choice 6
- Coordinate with transplant centers
- Monitor renal function closely if using adefovir or TDF
- Never use interferon 6
Liver transplant recipients:
- Combination of hepatitis B immunoglobulin (HBIG) plus nucleos(t)ide analogue to prevent recurrence 4
HIV coinfection:
- Use regimens active against both viruses
- Avoid entecavir monotherapy unless HIV RNA suppressed 3
Critical Pitfalls to Avoid
- Do not treat inactive carriers (HBeAg-negative, normal ALT, HBV DNA <2,000 IU/mL) 6
- Do not use low-barrier drugs (lamivudine, adefovir, telbivudine) as first-line therapy due to high resistance rates 4, 1, 2
- Do not stop treatment prematurely in cirrhotic patients—indefinite treatment is required 6, 3
- Do not use interferon in decompensated cirrhosis—risk of fatal hepatic decompensation 6
- Monitor for hepatocellular carcinoma with ultrasound and AFP every 6 months in all cirrhotic patients and high-risk non-cirrhotic patients, even with viral suppression 1, 2, 3, 9